Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms
Conditions
Interventions
Intervention1: Silodosin and mirabegron: Silodosin- alpha blocker, dosing of 8 mg once a day for 2 months to be taken orally
Mirabegron- Beta 3 agonist, dosing of 50 mg once a day for 2 months to be t
Sponsors
Sathaye Shekhar Ulhas
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients presenting to urology OPD with complaints of nocturia with documented BEP at PGIMER, Chandigarh. 2.Patients willing to participate in the study. 3.Age greater than 40 years
Exclusion criteria
Exclusion criteria: 1.Prostate cancer 2.Any contraindication to use mirabegron 3.Recurrent UTI 4.Patients with H/O AUR or PUC placement or patients who are on PUC. 5.Bladder stones. 6.Stricture urethra. 7.Psychogenic polydipsia 8.Prostate surgery in the past. 9.Spinal cord trauma, spinal disease affecting bladder function. 10.Patient not willing to participate in study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparing outcome of Silodosin vs Silodosin plus Mirabegron for nocturia in patients of BEP/LUTS. Timepoint: Baseline, at 1 month, at 2 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess difference in improvement of overall IPSS score between the two arms. 2. To compare change in sleep quality using ICIQ-NQoL score 3. To compare the adverse events in the two groups. Timepoint: Baseline, at 1 month, at 2 months | — |
Countries
India
Contacts
Public ContactSathaye Shekhar Ulhas
Post Graduation Institute of Medical Education and Research, Chandigarh
Outcome results
None listed